Lisa M Broad
Overview
Explore the profile of Lisa M Broad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical proof-of-concept results with a novel TRPA1 antagonist (LY3526318) in 3 chronic pain states
Mellado Lagarde M, Wilbraham D, Martins R, Zhao H, Jackson K, Johnson K, et al.
Pain
. 2024 Dec;
PMID: 39679712
Transient receptor potential ankyrin 1 (TRPA1) is implicated in physiological and pathological nociceptive signaling, but the clinical benefit of TRPA1 antagonists in chronic pain is not clearly demonstrated. LY3526318 is...
2.
Thompson K, Watson S, Zanato C, DallAngelo S, de Nooij J, Pace-Bonello B, et al.
Exp Physiol
. 2023 Sep;
109(1):81-99.
PMID: 37656490
A metabotropic glutamate receptor coupled to phospholipase D (PLD-mGluR) was discovered in the hippocampus over three decades ago. Its pharmacology and direct linkage to PLD activation are well established and...
3.
Bamps D, Blockeel A, Dreesen E, Marynissen H, Laenen J, Van Hecken A, et al.
Clin Pharmacol Ther
. 2023 Aug;
114(5):1093-1103.
PMID: 37562824
Transient receptor potential Ankyrin 1 (TRPA1) is an ion channel expressed by sensory neurons, where it mediates pain signaling. Consequently, it has emerged as a promising target for novel analgesics,...
4.
Brown A, Bradley S, Marshall F, Brown G, Bennett K, Brown J, et al.
Cell
. 2021 Nov;
184(24):5886-5901.e22.
PMID: 34822784
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative...
5.
Bradley S, Molloy C, Valuskova P, Dwomoh L, Scarpa M, Rossi M, et al.
Nat Chem Biol
. 2020 Feb;
16(3):240-249.
PMID: 32080630
Cholinesterase inhibitors, the current frontline symptomatic treatment for Alzheimer's disease (AD), are associated with low efficacy and adverse effects. M1 muscarinic acetylcholine receptors (M1 mAChRs) represent a potential alternate therapeutic...
6.
Broad L, Sanger H, Mogg A, Colvin E, Zwart R, Evans D, et al.
Br J Pharmacol
. 2018 Oct;
176(1):110-126.
PMID: 30276808
Background And Purpose: We aimed to identify and develop novel, selective muscarinic M receptor agonists as potential therapeutic agents for the symptomatic treatment of Alzheimer's disease. Experimental Approach: We developed...
7.
Bradley S, Molloy C, Bundgaard C, Mogg A, Thompson K, Dwomoh L, et al.
Mol Pharmacol
. 2018 Apr;
93(6):645-656.
PMID: 29695609
The realization of the therapeutic potential of targeting the M muscarinic acetylcholine receptor (mAChR) for the treatment of cognitive decline in Alzheimer's disease has prompted the discovery of M mAChR...
8.
Mogg A, Eessalu T, Johnson M, Wright R, Sanger H, Xiao H, et al.
J Pharmacol Exp Ther
. 2018 Apr;
365(3):602-613.
PMID: 29643252
In the search for improved symptomatic treatment options for neurodegenerative and neuropsychiatric diseases, muscarinic acetylcholine M1 receptors (M1 mAChRs) have received significant attention. Drug development efforts have identified a number...
9.
Felder C, Goldsmith P, Jackson K, Sanger H, Evans D, Mogg A, et al.
Neuropharmacology
. 2018 Jan;
136(Pt C):449-458.
PMID: 29374561
The cholinergic signalling system has been an attractive pathway to seek targets for modulation of arousal, cognition, and attention which are compromised in neurodegenerative and neuropsychiatric diseases. The acetylcholine muscarinic...
10.
Monn J, Henry S, Massey S, Clawson D, Chen Q, Diseroad B, et al.
J Med Chem
. 2018 Jan;
61(6):2303-2328.
PMID: 29350927
Multiple therapeutic opportunities have been suggested for compounds capable of selective activation of metabotropic glutamate 3 (mGlu) receptors, but small molecule tools are lacking. As part of our ongoing efforts...